RECOVERY & TISSUE REPAIR / COMPARE
Six Compounds, Side by Side
Where these six repair peptides and blends converge, where they diverge, and how far the evidence behind each one actually reaches.
The short version
This page lines up BPC-157, TB-500, GHK-Cu, KPV, Wolverine and KLOW on the dimensions that matter when reading research peptides: what kind of molecule each is, where it has been studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single most important caution. The headline: GHK-Cu has the most human (mostly topical) data; BPC-157 has the deepest animal record with three tiny human pilots; TB-500's evidence largely belongs to its full-length parent protein; KPV has no human trials; Wolverine and KLOW are blend extrapolations with no combination studies behind them. None is an approved medicine, and none is presented here with a human dose.
The comparison matrix
| Dimension | BPC-157 | TB-500 | GHK-Cu | KPV | Wolverine | KLOW |
|---|---|---|---|---|---|---|
| Peptide class | Stable gastric pentadecapeptide (15 aa) | Synthetic actin-binding fragment of thymosin beta-4 (7 aa) | Copper-binding tripeptide (3 aa) | Melanocortin-derived anti-inflammatory tripeptide (3 aa) | BPC-157 + TB-500 co-formulation | KPV + GHK-Cu + BPC-157 + TB-500 co-formulation |
| Most-studied in | Tendon, gut, muscle and nerve repair | Actin biology; cell migration and angiogenesis | Skin regeneration and matrix synthesis | Gut inflammation (colitis) | Component mechanisms separately; no combination study | Component mechanisms separately; no blend study |
| Evidence base (model) | Mostly rat; 3 small human pilots [2] | Mostly full-length Tβ4 (animal + 1 human Phase 1) [8][11] | In vitro + small human topical trials [16] | In vitro + mouse only; no human trials [20] | Extrapolated from each component alone [2][8] | Extrapolated from each component alone; community anecdote only [8] |
| Administration studied | IM, intragastric, IV pilot [3][5] | IV (full-length Tβ4), IP in animals [9][11] | Topical, ex vivo skin penetration [13][17] | Oral / PepT1-targeted delivery in mice [19][20] | Not studied as blend | Not studied as blend |
| Regulatory / WADA status | Not approved; WADA S0 prohibited | Not approved; WADA-prohibited | Cosmetic ingredient (topical); systemic unapproved | Not approved; not specifically WADA-listed | Not approved; both components WADA-prohibited | Not approved; TB-500 component WADA-prohibited |
| Key caution | Single-lab, preclinical-heavy record [2] | Fragment vs full-protein identity gap [8] | Poor skin permeability; pigmentation risk [13] | Entirely preclinical; no human PK [20] | No combination study; both components WADA-prohibited [8] | No blend study; pro-angiogenic + cancer caution; untested PKmismatch [8] |
Peptide class
The six span a wide size range and structural variety. BPC-157 is the largest single peptide at fifteen amino acids — a stable gastric pentadecapeptide. TB-500 is a seven-amino-acid fragment that holds the actin-binding sequence of the much larger thymosin beta-4 protein. GHK-Cu and KPV are both tripeptides (three amino acids), but they are structurally and functionally different: GHK-Cu is a copper carrier drawn from collagen, while KPV is the anti-inflammatory tail of the hormone alpha-MSH [22]. Wolverine and KLOW are not single peptides but co-formulations — two-component and four-component blends respectively.
Most-studied in
Each single peptide has a home territory in the literature. BPC-157's animal record is the broadest, spanning tendon, gut, muscle and nerve [6]. TB-500's research centers on actin biology and the cell migration and blood-vessel growth that follow from it [10]. GHK-Cu is overwhelmingly a skin-and-matrix story — collagen, elastin and dermal regeneration [16]. KPV is studied almost entirely in models of gut inflammation, particularly chemically induced colitis in mice [20]. For Wolverine and KLOW, "most-studied in" is the sum of the components studied individually; the blends themselves have no dedicated study territory.
Evidence base (model)
This is where the six genuinely separate. GHK-Cu has the most human data — mostly topical and small-scale, plus one 45-patient combination hair-loss trial [15][16]. BPC-157 has a deep animal record and three small uncontrolled human pilots [2]. TB-500 is the trickiest: its strongest human data — a Phase 1 IV safety study in 40 volunteers — used full-length thymosin beta-4, not the marketed fragment [8][11]. KPV has the least human footing of the four singles: no published human clinical trials [20]. Wolverine and KLOW sit at the bottom of the evidence hierarchy here: their human evidence is zero for the actual combination — only community anecdote and the inherited preclinical records of each component.
Administration studied
Routes follow the research questions. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot [3][5]. TB-500 / Tβ4 was given intravenously in the human Phase 1 study and intraperitoneally in animals [9][11]. GHK-Cu is studied topically, with ex vivo skin-penetration measurements quantifying dermal copper delivery [13][17]. KPV's recent work uses oral and PepT1-targeted nanoparticle delivery in mice, because the free peptide is quickly broken down [19][20]. Neither Wolverine nor KLOW has been administered in a formal study; the routes used in the peptide community are not from published clinical protocols.
Regulatory / WADA status
None of the six is an FDA- or EMA-approved medicine for systemic use. BPC-157 and TB-500 are both explicitly WADA-prohibited (BPC-157 under the S0 non-approved-substances category; TB-500/thymosin beta-4 under prohibited peptide/growth-factor categories) [8]. Because both Wolverine and KLOW contain these prohibited components, both blends implicate anti-doping rules in athletic contexts. GHK-Cu is legally sold as a topical cosmetic ingredient (Copper Tripeptide-1) but is unapproved for systemic or injectable use [13]. KPV is not specifically listed by name on the WADA Prohibited List, but as a non-approved peptide it warrants caution in sport contexts.
Key caution
Each compound carries a defining caveat. For BPC-157: a broad but internally consistent preclinical signal concentrated in one research group, with only three tiny human pilots [2]. For TB-500: the marketed fragment is not the molecule behind most of the efficacy data, plus a theoretical tumor-angiogenesis signal from the parent protein [8][10]. For GHK-Cu: poor skin permeability and a documented pigmentation risk [13]. For KPV: entirely preclinical with no human pharmacokinetics at all [20]. For Wolverine: no combination study, and both components are WADA-prohibited, making it a high-regulatory-risk blend extrapolated from component data [8]. For KLOW: all of the above for each component, plus the theoretical cancer/angiogenesis concern is compounded when three pro-angiogenic peptides are combined in one vial, and the pharmacokinetic mismatch between the four components makes matched exposures structurally unlikely [8]. The consistent thread: promising mechanisms, uneven and frequently early evidence.